3rd Sep 2018 09:44
LONDON (Alliance News) - Shares rose in SkinBioTherapeutics PLC on Monday as it said its SkinBiotix technology has met the stability criteria needed for its human study, and expects to start the study in September.
Shares in the skin-focused life science company rose 11% to 21.59 pence on Monday.
In May, SkinBioTherapeutics said the six week study will look at 120 participants with 'dry skin' and will measure visual assessments of skin dryness, skin hydration, and skin barrier function.
SkinBiotix will be applied as a cream three times daily, and the company said the entire study should take around eight weeks.
"Demonstrating the extended stability of the cream formulation was a key step to commencing the human study. This remains on track to start this month," said Chief Executive Officer Cath O'Neill.
Related Shares:
Skinbiotherap.